There are three aromatase inhibitors approved by the US Food and Drug Administration for the treatment of breast cancer: anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) (Barnadas et al., 2011; Merriam and Sikov, 2011). The gene discussed is CYP19A1; the disease is breast carcinoma.